Akebia Therapeutics Balance Sheet Health
Financial Health criteria checks 0/6
Akebia Therapeutics has a total shareholder equity of $-50.4M and total debt of $93.0M, which brings its debt-to-equity ratio to -184.5%. Its total assets and total liabilities are $207.1M and $257.5M respectively.
Key information
-184.5%
Debt to equity ratio
US$92.97m
Debt
| Interest coverage ratio | n/a |
| Cash | US$34.02m |
| Equity | -US$50.40m |
| Total liabilities | US$257.54m |
| Total assets | US$207.14m |
Recent financial health updates
Recent updates
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41%
Nov 08
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry
Aug 02Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
Apr 02There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise
Mar 19Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Jan 05Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump
Jun 23Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?
Mar 02Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky
Oct 07Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher
Aug 10Akebia regains rights to kidney disease therapy after termination of deals with Otsuka
Jun 30Financial Position Analysis
Short Term Liabilities: AKBA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: AKBA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: AKBA has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: AKBA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AKBA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AKBA has less than a year of cash runway if free cash flow continues to grow at historical rates of 20.3% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 11:54 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Akebia Therapeutics, Inc. is covered by 21 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Difei Yang | Aegis Capital Corporation |
| Jonathan Aschoff | Brean Capital |
| Jonathan Aschoff | B. Riley Wealth |